IM Cannabis Corp IMCC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IMCC is a good fit for your portfolio.
News
-
IMC to transfer its Oranim Pharmacy shares back to the seller
-
IM Cannabis and Flora Growth Partner to Bring Vessel Cannabis Accessories to the Israeli Market
-
Avant and IMC Execute BLK MKT™ Trademark Licensing Agreement for the German Medical Cannabis Market
-
IMC applauds the April 1st implementation of the new Israeli cannabis regulation, facilitating access for many new patients
-
IM Cannabis Reports 2023 Financial Results
-
IMC Expects Accelerated Growth in Germany from the Country's Groundbreaking Cannabis Legalization
-
IM Cannabis to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 28 at 9:00am ET
-
IM Cannabis Receives 180 Calendar Day Extension from the Nasdaq Stock Market to Regain Compliance with Bid Price Rule
Trading Information
- Previous Close Price
- $0.60
- Day Range
- $0.56–0.64
- 52-Week Range
- $0.21–1.43
- Bid/Ask
- $0.58 / $0.63
- Market Cap
- $7.64 Mil
- Volume/Avg
- 7 / 623,955
Key Statistics
- Price/Earnings (Normalized)
- 0.29
- Price/Sales
- 0.21
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 95
- Website
- https://www.imcannabis.com
Valuation
|
Metric
|
IMCC
|
|---|---|
Price/Earnings (Normalized) | 0.29 |
Price/Book Value | 2.22 |
Price/Sales | 0.21 |
Price/Cash Flow | — |
Price/Earnings
IMCC
Financial Strength
|
Metric
|
IMCC
|
|---|---|
Quick Ratio | 0.40 |
Current Ratio | 0.74 |
Interest Coverage | −3.48 |
Quick Ratio
IMCC
Profitability
|
Metric
|
IMCC
|
|---|---|
Return on Assets (Normalized) | −24.73% |
Return on Equity (Normalized) | −200.42% |
Return on Invested Capital (Normalized) | −48.97% |
Return on Assets
IMCC
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Tjhwptyjq | Wytvc | $71.2 Bil | |
ZTS
| Zoetis Inc Class A | Bxrjvnrnr | Jkdt | $68.3 Bil | |
HLN
| Haleon PLC ADR | Lqgzmpnv | Smkxn | $37.5 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Vrtmgglg | Gkfdn | $14.5 Bil | |
VTRS
| Viatris Inc | Dqmnqmw | Kyjym | $13.4 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Dpjxgbydd | Bfy | $11.9 Bil | |
CTLT
| Catalent Inc | Rrfdjrqf | Pfmmxp | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Klwscht | Fkmqg | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Fwcpfryvd | Xjkt | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Zcdzwqmvq | Cmyrcv | $3.5 Bil |